Erythropoietin administration to improve graft survival

• US 7,459,152 B2
• Filed: 04/23/2004
• Issued: 12/02/2008
• Est. Priority Date: 04/23/2003
• Status: Active Grant

• Current Assignee: Rush University Medical Center (Rush University)
• Original Assignee: Rush University Medical Center (Rush University)
• Inventors: Collier, Timothy J., Sortwell, Caryl E.
• Primary Examiner(s): Romeo; David S
• Assistant Examiner(s): Gamett; Daniel C
• Application Number:
  US10/830,705
• Publication Number:
  US 20040259071A1
• Time in Patent Office: 1,684 Days
• Field of Search: None
• US Class Current: 424/93.1
• CPC Class Codes: A01N 1/0205 Chemical aspects
• CPC Class Codes: A01N 1/0226 Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: C12N 2501/14 Erythropoietin [EPO]

Abstract

The present invention provides methods, compounds and kits for increasing the viability of cells. The methods involve treating cells that make up a tissue graft with erythropoietin before, during or after delivery or administration. The method can employ cells of different types, including cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson'"'"'s disease, Alzheimer'"'"'s disease, Huntington'"'"'s disease, epilepsy, and traumatic brain or spinal cord injury.

Claims

1. A method of treating Parkinsonism comprising:

(a) contacting a tissue graft comprising differentiated dopamine producing neurons with an effective amount of exogenous erythropoietin (EPO) or an isoform or peptide analog of EPO or administering the EPO, an isoform or peptide analog of EPO or combinations thereof to the tissue graft; and

(b) administering the tissue graft into a compatible recipient neuronal tissue in a subject suffering from Parkinsonism, wherein the survival of cells in the tissue graft is increased, compared to cells in a tissue graft not contacted with EPO or an isoform or peptide analog thereof,

wherein step (a) occurs prior to step (b).

2. The method of claim 1 wherein the effective amount of EPO or the analog thereof is from about 10 IU/mL to about 500 IU/mL.

3. The method of claim 1 wherein the compatible recipient neuronal tissue is brain tissue.

4. The method of claim 1 wherein the EPO or the analog thereof is recombinant human EPO.

5. The method of claim 1 wherein the dopamine producing neurons of the tissue graft are embryonic mesencephalic cells or are obtained from stem cells, neural stem cells, or neural progenitor cells.